ArticleDiscover oncology2025
SGSM1 as a pan-cancer biomarker: multi-omics insights into immune regulation, prognostic value, and therapeutic implications.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIt has been shown that the protein known as Small G Protein Signaling Modulator 1 (SGSM1), which has both a TBC domain and RUN domain and was linked to RAB- and RAP-mediated cellular signaling, is involved in the advancement of tumors. It is unclear, however, whether SGSM1 is pivotal in the development of pan-cancer.
methodsThe Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases were used to examine the expression patterns of SGSM1 in a variety of malignancies. The SGSM1 protein expression levels were validated in the HPA and UALCAN databases. Protein-gene interaction analysis was carried out using data from the STRING and GeneMANIA databases. The predictive significance of SGSM1 expression was examined via the K-M plotter and survival data analyses and included OS, PFI, and DSS. For the purpose of conducting SGSM1-related GO and KEGG enrichment analyses, the R program "clusterProfiler" was utilized. We analyzed the TISIDB database in search of links between SGSM1 expression and immune or molecular subtypes. In addition, we examined how the expression of SGSM1 is linked to that of immune-related genes.
resultsIn TCGA, SGSM1 expression was shown to be downregulated in the vast majority of malignancies, including HNSC, COAD, BRCA, and KIRP, and to indicate an unfavorable prognosis in cancers such as KIRC, LGG, MESO, PAAD, and UCEC. The expression of SGSM1 is highly variable across molecular and immunological cancer subtypes. In COAD, KIRC, PAAD, and PRAD tissues, the SGSM1 protein was downregulated in comparison with normal tissue. The AUC for ten different cancers predicted by SGSM1 was more than 0.7, indicating a considerable degree of accuracy. The Ras signaling pathway dominated the enriched KEGG pathways. SGSM1 in KIRC was discovered to have a negative link to immune-related genes, including CTLA4, PDCD1, TIGIT, LAG-3, and CD48.
conclusionsThe findings demonstrated that SGSM1 could be used as a novel biological marker for a wide variety of tumor types. SGSM1 may be implicated in the tumor immune microenvironment, which holds promise as a putative novel treatment target for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.